Protara Therapeutics, Inc.
TARA· Nasdaq
TARAProtara Therapeutics, Inc.
Filed Aug 6, 2024 · 10-Q · 37 days after period end · 0001213900-24-065380
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$9.51M | -$11.29M | -$8.54M | -$12.78M |
| EPS Diluted | -$0.45 | -$1.00 | -$0.76 | -$1.14 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protara Therapeutics, Inc. · CIK 1359931 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 6, 2024 · 37 d after period end
